-
1
-
-
33645526144
-
Cancer statistics, 2006
-
Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ,. Cancer statistics, 2006. CA Cancer J Clin 2006; 56: 106-130.
-
(2006)
CA Cancer J Clin
, vol.56
, pp. 106-130
-
-
Jemal, A.1
Siegel, R.2
Ward, E.3
Murray, T.4
Xu, J.5
Smigal, C.6
Thun, M.J.7
-
2
-
-
0036835534
-
Sequencing hormonal ablation and radiotherapy in prostate cancer: A molecular and therapeutic prespective (Review)
-
Hill B, Kyprianou N,. Sequencing hormonal ablation and radiotherapy in prostate cancer: A molecular and therapeutic prespective (Review). Oncol Rep 2002; 9: 1151-1156.
-
(2002)
Oncol Rep
, vol.9
, pp. 1151-1156
-
-
Hill, B.1
Kyprianou, N.2
-
3
-
-
22144475857
-
Recent progress in management of advanced prostate cancer
-
Kantoff P,. Recent progress in management of advanced prostate cancer. Oncology (Williston Park) 2005; 19: 631-636. (Pubitemid 350042593)
-
(2005)
Oncology
, vol.19
, Issue.5
, pp. 631-636
-
-
Kantoff, P.1
-
4
-
-
36248968106
-
Docetaxel plus prednisone versus mitoxantrone plus prednisone for metastatic hormone-refractory prostate cancer in chinese patients: Experience of a single center
-
DOI 10.1159/000109714
-
Zhang HL, Ye DW, Yao XD, Dai B, Zhang SL, Shen YJ, Zhu Y, Zhang W,. Docetaxel plus prednisone versus mitoxantrone plus prednisone for metastatic hormone-refractory prostate cancer in Chinese patients: Experience of a single center. Urol Int 2007; 79: 307-311. (Pubitemid 350136515)
-
(2007)
Urologia Internationalis
, vol.79
, Issue.4
, pp. 307-311
-
-
Zhang, H.L.1
Ye, D.W.2
Yao, X.D.3
Dai, B.4
Zhang, S.L.5
Shen, Y.J.6
Zhu, Y.7
Zhang, W.8
-
5
-
-
4444242518
-
Targeted inhibition of the epidermal growth factor receptor-tyrosine kinase by ZD1839 ('Iressa') induces cell-cycle arrest and inhibits proliferation in prostate cancer cells
-
DOI 10.1002/jcp.20045
-
Sgambato A, Camerini A, Faraglia B, Ardito R, Bianchino G, Spada D, Boninsegna A, Valentini V, Cittadini A,. Targeted inhibition of the epidermal growth factor receptor-tyrosine kinase by ZD1839 ('Iressa') induces cell-cycle arrest and inhibits proliferation in prostate cancer cells. J Cell Physiol 2004; 201: 97-105. (Pubitemid 39187048)
-
(2004)
Journal of Cellular Physiology
, vol.201
, Issue.1
, pp. 97-105
-
-
Sgambato, A.1
Camerini, A.2
Faraglia, B.3
Ardito, R.4
Bianchino, G.5
Spada, D.6
Boninsegna, A.7
Valentini, V.8
Cittadini, A.9
-
6
-
-
0020933452
-
Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors
-
Sato JD, Kawamoto T, Le AD, Mendelsohn J, Polikoff J, Sato GH,. Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors. Mol Biol Med 1983; 1: 511-529.
-
(1983)
Mol Biol Med
, vol.1
, pp. 511-529
-
-
Sato, J.D.1
Kawamoto, T.2
Le, A.D.3
Mendelsohn, J.4
Polikoff, J.5
Sato, G.H.6
-
7
-
-
0029991439
-
Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer
-
Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L, Sklarin NT, Seidman AD, Hudis CA, Moore J, Rosen PP, Twaddell T, Henderson IC, Norton L,. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 1996; 14: 737-744.
-
(1996)
J Clin Oncol
, vol.14
, pp. 737-744
-
-
Baselga, J.1
Tripathy, D.2
Mendelsohn, J.3
Baughman, S.4
Benz, C.C.5
Dantis, L.6
Sklarin, N.T.7
Seidman, A.D.8
Hudis, C.A.9
Moore, J.10
Rosen, P.P.11
Twaddell, T.12
Henderson, I.C.13
Norton, L.14
-
8
-
-
34548456523
-
A phase II trial of gefitinib in patients with non-metastatic hormone-refractory prostate cancer
-
DOI 10.1111/j.1464-410X.2007.07121.x
-
Small EJ, Fontana J, Tannir N, DiPaola RS, Wilding G, Rubin M, Iacona RB, Kabbinavar FF,. A phase II trial of gefitinib in patients with non-metastatic hormone-refractory prostate cancer. BJU Int 2007; 100: 765-769. (Pubitemid 47360196)
-
(2007)
BJU International
, vol.100
, Issue.4
, pp. 765-769
-
-
Small, E.J.1
Fontana, J.2
Tannir, N.3
Dipaola, R.S.4
Wilding, G.5
Rubin, M.6
Iacona, R.B.7
Kabbinavar, F.F.8
-
9
-
-
0242692686
-
Growth factor receptor tyrosine kinase inhibitors; clinical development and potential for prostate cancer therapy
-
DOI 10.1097/01.ju.0000095022.80033.d3
-
Blackledge G,. Growth factor receptor tyrosine kinase inhibitors; clinical development and potential for prostate cancer therapy. J Urol 2003; 170: S77-S83 discussion S83. (Pubitemid 37413947)
-
(2003)
Journal of Urology
, vol.170
, Issue.6
-
-
Blackledge, G.1
Sellers, W.R.2
Smith, M.R.3
-
10
-
-
0030993717
-
Temozolomide: A review of its discovery, chemical properties, pre-clinical development and clinical trials
-
DOI 10.1016/S0305-7372(97)90019-0
-
Newlands ES, Stevens MF, Wedge SR, Wheelhouse RT, Brock C,. Temozolomide: A review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat Rev 1997; 23: 35-61. (Pubitemid 27273454)
-
(1997)
Cancer Treatment Reviews
, vol.23
, Issue.1
, pp. 35-61
-
-
Newlands, E.S.1
Stevens, M.F.G.2
Wedge, S.R.3
Wheelhouse, R.T.4
Brock, C.5
-
11
-
-
0028858706
-
Increased killing of prostate, breast, colon, and lung tumor cells by the combination of inactivators of O6-alkylguanine-DNA alkyltransferase and N,N'-bis(2-chloroethyl)-N-nitrosourea
-
Pegg AE, Swenn K, Chae MY, Dolan ME, Moschel RC,. Increased killing of prostate, breast, colon, and lung tumor cells by the combination of inactivators of O6-alkylguanine-DNA alkyltransferase and N,N'-bis(2-chloroethyl)-N- nitrosourea. Biochem Pharmacol 1995; 50: 1141-1148.
-
(1995)
Biochem Pharmacol
, vol.50
, pp. 1141-1148
-
-
Pegg, A.E.1
Swenn, K.2
Chae, M.Y.3
Dolan, M.E.4
Moschel, R.C.5
-
12
-
-
33745123646
-
The combi-targeting concept: Synthesis of stable nitrosoureas designed to inhibit the epidermal growth factor receptor (EGFR)
-
DOI 10.1021/jm0600390
-
Domarkas J, Dudouit F, Williams C, Qiyu Q, Banerjee R, Brahimi F, Jean-Claude BJ,. The combi-targeting concept: Synthesis of stable nitrosoureas designed to inhibit the epidermal growth factor receptor (EGFR). J Med Chem 2006; 49: 3544-3552. (Pubitemid 43902460)
-
(2006)
Journal of Medicinal Chemistry
, vol.49
, Issue.12
, pp. 3544-3552
-
-
Domarkas, J.1
Dudouit, F.2
Williams, C.3
Qiyu, Q.4
Banerjee, R.5
Brahimi, F.6
Jean-Claude, B.J.7
-
13
-
-
0027501429
-
Schedule-dependent synergism of edatrexate and cisplatin in combination in the A549 lung-cancer cell line as assessed by median-effect analysis
-
DOI 10.1007/BF00686223
-
Perez EA, Hack FM, Webber LM, Chou TC,. Schedule-dependent synergism of edatrexate and cisplatin in combination in the A549 lung-cancer cell line as assessed by median-effect analysis. Cancer Chemother Pharmacol 1993; 33: 245-250. (Pubitemid 23361074)
-
(1993)
Cancer Chemotherapy and Pharmacology
, vol.33
, Issue.3
, pp. 245-250
-
-
Perez, E.A.1
Hack, F.M.2
Webber, L.M.3
Chou, T.-C.4
-
14
-
-
0030514288
-
Comparison of two colorimetric assays as cytotoxicity endpoints for an in vitro screen for antitumour agents
-
Fricker SP, Buckley RG,. Comparison of two colorimetric assays as cytotoxicity endpoints for an in vitro screen for antitumor agents. Anticancer Res 1996; 16: 3755-3760. (Pubitemid 27085044)
-
(1996)
Anticancer Research
, vol.16
, Issue.6
, pp. 3755-3760
-
-
Fricker, S.P.1
Buckley, R.G.2
-
15
-
-
0035119740
-
Design of a chimeric 3-methyl-1,2,3-triazene with mixed receptor tyrosine kinase and DNA damaging properties: A novel tumor targeting strategy
-
Matheson SL, McNamee J, Jean-Claude BJ,. Design of a chimeric 3-methyl-1,2,3-triazene with mixed receptor tyrosine kinase and DNA damaging properties: A novel tumor targeting strategy. J Pharmacol Exp Ther 2001; 296: 832-840. (Pubitemid 32187355)
-
(2001)
Journal of Pharmacology and Experimental Therapeutics
, vol.296
, Issue.3
, pp. 832-840
-
-
Matheson, S.L.1
McNamee, J.2
Jean-Claude, B.J.3
-
16
-
-
0036899978
-
Studies with CWR22 xenografts in nude mice suggest that ZD1839 may have a role in the treatment of both androgen-dependent and androgen-independent human prostate cancer
-
Sirotnak FM, She Y, Lee F, Chen J, Scher HI,. Studies with CWR22 xenografts in nude mice suggest that ZD1839 may have a role in the treatment of both androgen-dependent and androgen-independent human prostate cancer. Clin Cancer Res 2002; 8: 3870-3876. (Pubitemid 35424782)
-
(2002)
Clinical Cancer Research
, vol.8
, Issue.12
, pp. 3870-3876
-
-
Sirotnak, F.M.1
She, Y.2
Lee, F.3
Chen, J.4
Scher, H.I.5
-
17
-
-
0000360901
-
Synthesis of potential anticancer agents. XXIX. 5-Diazoimidazole-4- carboxamide and 5-diazo-v-triazole-4-carboxamide
-
Shealy YF, Struck RF, Holum LB, Montgomery JA,. Synthesis of potential anticancer agents. XXIX. 5-Diazoimidazole-4-carboxamide and 5-diazo-v-triazole- 4-carboxamide. J Org Chem 1961; 26: 2396-2401.
-
(1961)
J Org Chem
, vol.26
, pp. 2396-2401
-
-
Shealy, Y.F.1
Struck, R.F.2
Holum, L.B.3
Montgomery, J.A.4
-
18
-
-
0025361453
-
Antitumor imidazotetrazines. 20. Preparation of the 8-acid derivative of mitozolomide and its utility in the preparation of active antitumor agents
-
Horspool KR, Stevens MF, Newton CG, Lunt E, Walsh RJ, Pedgrift BL, Baig GU, Lavelle F, Fizames C,. Antitumor imidazotetrazines. 20. Preparation of the 8-acid derivative of mitozolomide and its utility in the preparation of active antitumor agents. J Med Chem 1990; 33: 1393-1399. (Pubitemid 20148375)
-
(1990)
Journal of Medicinal Chemistry
, vol.33
, Issue.5
, pp. 1393-1399
-
-
Horspool, K.R.1
Stevens, M.F.G.2
Newton, C.G.3
Lunt, E.4
Walsh, R.J.A.5
Pedgrift, B.L.6
Baig, G.U.7
Lavelle, F.8
Fizames, C.9
-
19
-
-
0023123974
-
Antitumor imidazotetrazines. 14. Synthesis and antitumor activity of 6- and 8-substituted imidazo[5,1-d]-1,2,3,5-tetrazinones and 8-substituted pyrazolo[5,1-d]-1,2,3,5-tetrazinones
-
DOI 10.1021/jm00385a018
-
Lunt E, Newton CG, Smith C, Stevens GP, Stevens MFG, Straw CG, Walsh RJA, Warren PJ, Fizames C, et al. Antitumor imidazotetrazines. 14. Synthesis and antitumor activity of 6- and 8-substituted imidazo[5,1-d]-1,2,3,5-tetrazinones and 8-substituted pyrazolo[5,1-d]-1,2,3,5-tetrazinones. J Med Chem 1987; 30: 357-366. (Pubitemid 17003808)
-
(1987)
Journal of Medicinal Chemistry
, vol.30
, Issue.2
, pp. 357-366
-
-
Lunt, E.1
Newton, C.G.2
Smith, C.3
-
20
-
-
37049075486
-
Antitumor imidazotetrazines. Part 31. the synthesis of isotopically labeled temozolomide and a multinuclear (1H, 13C, 15N) magnetic resonance investigation of temozolomide and mitozolomide. J Chem Soc
-
Wheelhouse RT, Wilman DEV, Thomson W, Stevens MFG,. Antitumor imidazotetrazines. Part 31. The synthesis of isotopically labeled temozolomide and a multinuclear (1H, 13C, 15N) magnetic resonance investigation of temozolomide and mitozolomide. J Chem Soc. Perkin Trans 1: 1995; 249-252.
-
(1995)
Perkin Trans
, vol.1
, pp. 249-252
-
-
Wheelhouse, R.T.1
Wilman, D.E.V.2
Thomson, W.3
Stevens, M.F.G.4
-
21
-
-
33845688396
-
Type II combi-molecules: Design and binary targeting properties of the novel triazolinium-containing molecules JDD36 and JDE05
-
DOI 10.1097/CAD.0b013e3280115fe8, PII 0000181320070200000008
-
Qiu Q, Domarkas J, Banerjee R, Katsoulas A, McNamee JP, Jean-Claude BJ,. Type II combi-molecules: Design and binary targeting properties of the novel triazolinium-containing molecules JDD36 and JDE05. Anti Cancer Drugs 2007; 18: 171-177. (Pubitemid 44967427)
-
(2007)
Anti-Cancer Drugs
, vol.18
, Issue.2
, pp. 171-177
-
-
Qiu, Q.1
Domarkas, J.2
Banerjee, R.3
Katsoulas, A.4
McNamee, J.P.5
Jean-Claude, B.J.6
-
22
-
-
0035893560
-
Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo
-
Moulder SL, Yakes FM, Muthuswamy SK, Bianco R, Simpson JF, Arteaga CL,. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo. Cancer Res 2001; 61: 8887-8895. (Pubitemid 34013905)
-
(2001)
Cancer Research
, vol.61
, Issue.24
, pp. 8887-8895
-
-
Moulder, S.L.1
Yakes, F.M.2
Muthuswamy, S.K.3
Bianco, R.4
Simpson, J.F.5
Arteaga, C.L.6
-
23
-
-
0141792695
-
The combi-targeting concept: Chemical dissection of the dual targeting properties of a series of "combi-triazenes"
-
DOI 10.1021/jm030142e
-
Rachid Z, Brahimi F, Katsoulas A, Teoh N, Jean-Claude BJ,. The combi-targeting concept: Chemical dissection of the dual targeting properties of a series of "Combi-Triazenes ". J Med Chem 2003; 46: 4313-4321. (Pubitemid 37153012)
-
(2003)
Journal of Medicinal Chemistry
, vol.46
, Issue.20
, pp. 4313-4321
-
-
Rachid, Z.1
Brahimi, F.2
Katsoulas, A.3
Teoh, N.4
Jean-Claude, B.J.5
-
24
-
-
0021795414
-
Experimental antitumor activity against murine tumor model systems of 8-carbamoyl-3-(2-chloroethyl)imidazo[5,1-d]-1,2,3,5-tetrazin- 4(3H)-one (mitozolomide), a novel broad-spectrum agent
-
Hickman JA, Stevens MF, Gibson NW, Langdon SP, Fizames C, Lavelle F, Atassi G, Lunt E, Tilson RM,. Experimental antitumor activity against murine tumor model systems of 8-carbamoyl-3-(2-chloroethyl)imidazo[5,1-d]-1,2,3,5- tetrazin-4(3 H)-one (mitozolomide), a novel broad-spectrum agent. Cancer Res 1985; 45: 3008-3013. (Pubitemid 15007165)
-
(1985)
Cancer Research
, vol.45
, Issue.7
, pp. 3008-3013
-
-
Hickman, J.A.1
Stevens, M.F.G.2
Gibson, N.W.3
-
25
-
-
32144441841
-
Epidermal growth factor receptor inhibitor (PD168393) potentiates cytotoxic effects of paclitaxel against androgen-independent prostate cancer cells
-
DOI 10.1016/j.bcp.2005.12.009, PII S0006295205008348
-
Pu Y-S, Hsieh M-W, Wang C-W, Liu G-Y, Huang C-Y, Lin C-C, Guan J-Y, Lin S-R, Hour T-C,. Epidermal growth factor receptor inhibitor (PD168393) potentiates cytotoxic effects of paclitaxel against androgen-independent prostate cancer cells. Biochem Pharmacol 2006; 71: 751-760. (Pubitemid 43208831)
-
(2006)
Biochemical Pharmacology
, vol.71
, Issue.6
, pp. 751-760
-
-
Pu, Y.-S.1
Hsieh, M.-W.2
Wang, C.-W.3
Liu, G.-Y.4
Huang, C.-Y.5
Lin, C.-C.6
Guan, J.-Y.7
Lin, S.-R.8
Hour, T.-C.9
-
26
-
-
5044220098
-
Sustained antiproliferative mechanisms by RB24, a targeted precursor of multiple inhibitors of epidermal growth factor receptor and a DNA alkylating agent in the A431 epidermal carcinoma of the vulva cell line
-
DOI 10.1038/sj.bjc.6602098
-
Banerjee R, Rachid Z, Qiu Q, McNamee JP, Tari AM, Jean-Claude BJ,. Sustained antiproliferative mechanisms by RB24, a targeted precursor of multiple inhibitors of epidermal growth factor receptor and a DNA alkylating agent in the A431 epidermal carcinoma of the vulva cell line. Br J Cancer 2004; 91: 1066-1073. (Pubitemid 39336244)
-
(2004)
British Journal of Cancer
, vol.91
, Issue.6
, pp. 1066-1073
-
-
Banerjee, R.1
Rachid, Z.2
Qiu, Q.3
McNamee, J.P.4
Tari, A.M.5
Jean-Claude, B.J.6
-
27
-
-
77953759248
-
The combi-targeting concept: Selective targeting of the epidermal growth factor receptor (EGFR)- and Her2-expressing cancer cells by the complex combi-molecule RB24 (NSC 741279)
-
Banerjee R, Huang Y, McNamee JP, Todorova MI, Jean-Claude BJ,. The combi-targeting concept: Selective targeting of the epidermal growth factor receptor (EGFR)- and Her2-expressing cancer cells by the complex combi-molecule RB24 (NSC 741279). J Pharmacol Exp Ther 2010; 334: 9-20.
-
(2010)
J Pharmacol Exp Ther
, vol.334
, pp. 9-20
-
-
Banerjee, R.1
Huang, Y.2
McNamee, J.P.3
Todorova, M.I.4
Jean-Claude, B.J.5
-
28
-
-
77950831852
-
Subcellular distribution of a fluorescence-labeled combi-molecule designed to block epidermal growth factor receptor tyrosine kinase and damage DNA with a green fluorescent species
-
Todorova M, Larroque A-L, Dauphin-Pierre S, Fang YQ, Jean-Claude BJ,. Subcellular distribution of a fluorescence-labeled combi-molecule designed to block epidermal growth factor receptor tyrosine kinase and damage DNA with a green fluorescent species. Mol Cancer Ther 2010; 9: 869-882.
-
(2010)
Mol Cancer Ther
, vol.9
, pp. 869-882
-
-
Todorova, M.1
Larroque, A.-L.2
Dauphin-Pierre, S.3
Fang, Y.Q.4
Jean-Claude, B.J.5
|